Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

We evaluated a combination of transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate versus solifenacin alone in the treatment of overactive bladder (OAB). Ninety-seven female outpatients with OAB were screened for this double-blind randomized controlled study. Eighty-six patie...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-06, Vol.16 (6), p.e0253040-e0253040
Main Authors: Zhang, Yumeng, Wang, Shaoyong, Zu, Shulu, Zhang, Chanjuan
Format: Article
Language:English
Subjects:
Biology and Life Sciences
Bladder
Care and treatment
Clinical trials
Complications and side effects
Constipation
Diaries
Double-blind studies
Drug therapy
Electrodes
Evaluation
Feet
Medicine and Health Sciences
Muscles
Pain
Paresthesia
Patient outcomes
Patients
Questionnaires
Stimulation
Transcutaneous electrical nerve stimulation
Transcutaneous electrical nerve stimulation-TENS
Urinary incontinence
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated a combination of transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate versus solifenacin alone in the treatment of overactive bladder (OAB). Ninety-seven female outpatients with OAB were screened for this double-blind randomized controlled study. Eighty-six patients who met our inclusion criteria were divided randomly into two groups. In group A (43 patients), patients received oral solifenacin and "fake" TENS on the foot; in group B (43 patients), patients received oral solifenacin and effective TENS on the foot. Improvements in OAB symptoms were assessed by Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire (OAB-q), voiding diaries and urodynamic tests. 70 of 86 patients (36 in group A, 34 in group B) completed the 2 months of treatment and 3 months of follow-up. Statistically, the maximum bladder volume and OAB symptoms of both groups improved significantly after treatment. The improvement in group B was significantly better than that in group A, as indicated by the maximum bladder volume, OAB-q score and voiding diary. Some mild adverse effects were observed, including dry mouth, stomach upset, constipation, muscle pain and local paresthesia. The combination of TENS and solifenacin was more effective in improving OAB symptoms than solifenacin alone.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0253040